Approval for Additional Indications for the Selective Antithrombin Agents, Novastan® HI Injection 10 mg/2mL and Slonnon® HI Injection 10 mg/2mL

May 20, 2011 Mitsubishi Tanabe Pharma Corporation DAIICHI SANKYO COMPANY, LIMITED Approval for Additional Indications for the Selective Antithrombin Agents, Novastan® HI Injection 10 mg/2mL and Slonnon® HI Injection 10 mg/2mL Mitsubishi Tanabe Pharma Corporation (H ead Office: Osaka, President & CEO: Michihiro Tsuchiya) and Daiichi Sankyo Company, Limited (Head Office: Tokyo, President & CEO: Joji Nakayama) announced today that they obtained approval in Japan for additional indications for the selective antithrombin agents “Novastan® HI injection 10 mg/2mL (manufacture and sale: Mitsubishi Tanabe Pharma Corporation)” and “Slonnon ® HI injection 10 mg/2mL (manufacture and sale: Daiichi Sankyo Company, Limited)” (generic name for both drugs: argatroban hydrate), for prevention of blood coagulation in under dialysis in patients with heparin-induced thrombocytopenia (HIT) type II and percutaneous coronary intervention in patients with HIT type II including those who have a risk of developing, as of May 20, 2011. HIT type II is a serious disorder that can lead to fatal thromboembolism. In Japan, argatroban hydrate has been approved on July 16, 2008 for inhibition of thrombosis in HIT type II. Overseas , argatroban hydrate has been approved in 11 countries, including the U.S. in 2000. Both companies expect to contribute furthe r to needs in clinical practice through providing argaroban hydrat e to HIT type II patients with these additional indications approved today. Contacts: Mitsubishi Tanabe Pharma Corporation Corporate Communications Department Tel：+81-6-6205-5211 Daiichi Sankyo Company, Limited Corporate Communications Department Tel：+81-3-6225-1126

The release as fetched from its publisher. tanabe-pharma.com ↗